{"filing":{"accession_number":"0001493152-26-042506","cik":"0001213037","ticker":"CRDF","company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm"},"events":[{"id":33197,"run_id":30518,"accession_number":"0001493152-26-042506","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses entry into a material definitive agreement—a Settlement Agreement and Amendment to License Agreement with Nerviano Medical Sciences—that resolves litigation and materially restructures Cardiff's exclusive worldwide license to develop and commercialize onvansertib, its lead PLK1 inhibitor. The Amendment includes revised royalty structures, development milestones, assignment provisions tied to Phase III outcomes, and governance rights (board observer, Scientific Advisory Board seat), fundamentally altering the parties' ongoing relationship and Cardiff's rights to its lead asset. While styled as a settlement and license amendment rather than a traditional M\u0026A transaction, the material restructuring of Cardiff's exclusive rights and obligations to its lead product candidate constitutes a material change in the company's strategic position and financial obligations.","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":36575,"accession_number":"0001493152-26-042506","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a material definitive agreement—a Settlement Agreement and Amendment to License Agreement with Nerviano Medical Sciences—that resolves litigation and materially restructures Cardiff's exclusive worldwide license to develop and commercialize onvansertib, its lead PLK1 inhibitor. The Amendment includes revised royalty structures, development milestones, assignment provisions tied to Phase III outcomes, and governance rights (board observer, Scientific Advisory Board seat), fundamentally altering the parties' ongoing relationship and Cardiff's rights to its lead asset. While styled as a settlement and license amendment rather than a traditional M\u0026A transaction, the material restructuring of Cardiff's exclusive rights and obligations to its lead product candidate constitutes a material change in the company's strategic position and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T13:28:50.149118+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-09-14"}]}